Korean J Urol.  2006 Nov;47(11):1191-1196. 10.4111/kju.2006.47.11.1191.

The Efficacy of Terazosin in the Management of Chronic Pelvic Pain Syndrome (CPPS): Comparison between Category IIIa and IIIb

• Jung YH
• Kim JG
• Cho IR

• KMID: 2294278
• DOI: http://doi.org/10.4111/kju.2006.47.11.1191

Abstract

Purpose
To evaluate the efficacy of terazosin in chronic pelvic pain syndrome (CPPS) and compare the effect of terazosin between CPPS IIIa and IIIb. Materials end Methods: Between January 2004 and February 2005, CPPS patients, aged 45 or below, with a small size prostate (Results
The changes in the NIH-CPSI domains (pain, voiding symptom, quality of life, total) and Qmax of the T group were more significantly improved than those in the non T group (p<0.05). For category IIIa (n=71), the T group (n=42) showed significant improvements in all NIH-CPSI domains and the Qmax (p<0.05); whereas, the non-T group (n=29) only showed significant improvement in the pain and total scores in the NIH-CPSI domains (p<0.05). However, in a comparison between both category IIIa groups, there were no significant difference in the changes in the NIH-CPSI domains, with the exception of the Qmax (p>0.05). In category IIIb (n=56), the T group (n=29) showed significant improvements in all NIH-CPSI domains and the Qmax (p<0.05), but the non-T group (n=27) showed no significant improvement in the NIH-CPSI domains or the Qmax (p>0.05). Comparing both category IIIb groups, the T group showed a greater improvement in the pain score in the NIH-CPSI domains and the Qmax than the non-T group.
Conclusions
Terazosin was effective in all domains of the symptom score and in the Qmax for CPPS.

Keyword

Prostatitis; Pelvic pain; Syndrome; Terazosin

MeSH Terms

Humans
Massage
Pelvic Pain*
Prostate
Prostatitis
Quality of Life
Ultrasonography
Urinalysis

Reference

1. Nickel JC. Prostatitis: myths and realities. Urology. 1998. 51:362–366.

2. Cho IR. Evaluation and treatment of patients with prostatitis. Korean J Androl. 2005. 20:1–11.

3. Cho IR, Park SC, Park SS. The prevalence of the symptoms of the prostate syndrome patients under 50. Korean J Urol. 1998. 39:751–756.

4. Wenninger K, Heiman JR, Rothman I, Berghuis JP, Berger RE. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol. 1996. 155:965–968.

5. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999. 282:236–237.

6. Schaeffer AJ, Datta NS, Fowler JE Jr, Krieger JN, Litwin MS, Nadler RB, et al. Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urology. 2002. 60:Suppl 6. 1–4.

7. Donker PJ, Ivanovici F, Noach EL. Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br J Urol. 1972. 44:180–193.

8. Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Alfthan O. Increased intraprostatic pressure in patients with chronic prostatitis. Urol Res. 1999. 27:277–279.

9. Mehik A, Helstrom P, Nickel JC, Kilponen A, Leskinen M, Sarpola A, et al. The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. J Urol. 2002. 167:137–140.

10. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968. 5:492–518.

11. Nickel JC, Pontari M, Moon T, Gittleman M, Malek G, Farrington J, et al. A randomized placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003. 169:1401–1405.

12. Datta NS. Role of alpha-blockers in the treatment of chronic prostatitis. Urology. 2002. 69:Suppl 6. 27–28.

13. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol. 1998. 159:883–887.

14. Barbalias GA. Why alpha-blockers in prostatitis? Eur Urol. 2003. 60:27–29.

15. de la Rosette JJ, Karthaus HF, van Kerrebroeck PE, de Boo T, Debruyne FM. Research in 'prostatitis syndrome': the use of alfuzocin (a new alpha 1-receptor-blocking agents) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. Eur Urol. 1992. 22:222–227.

16. Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom PJ. Alfuzosin treatment for chronic prostatitis-chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology. 2003. 62:425–429.

17. Kim SJ, Ha JS, Lee SJ, Cho YH, Yoon MS. Clinical effect of tamsulosin in noninflammatory chronic pelvic pain syndrome. Korean J Urol. 2003. 44:120–123.

18. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol. 2004. 171:1594–1597.

19. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'leary MP, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis-chronic pelvic pain syndrome. Ann Intern Med. 2004. 141:581–589.

20. Neal DE Jr, Moon TD. Use of terazocin in prostatodynia and validation of a symptom score questionnaire. Urology. 1994. 43:460–465.

21. Gul O, Eroglu M, Ozok U. Use of terazosin in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol. 2001. 32:433–436.

22. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol. 2003. 169:592–596.